NCT06802718

Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia

A Prospective Randomized Controlled Trial of Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 96 (estimated)
• Sponsor: Peking University People's Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This research focuses on a prospective, randomized, controlled trial of "Interferon-alpha as maintenance therapy for favorable-risk acute myeloid leukemia." By fully utilizing prospective, randomized, controlled clinical trial and studying the negative conversion of MRD and the survival of favorable-risk AML patients, it aims to explore the efficacy and safety of Interferon-alpha in the maintenance treatment of favorable-risk AML and identify effective measures to prevent relapse, thereby improving the survival of favorable-risk AML patients. The primary endpoint is the negative conversion of MRD at 6 months. The secondary endpoints include the 2-year cumulative incidence of relapse, 2-year event-free survival (EFS), 2-year overall survival (OS), and safety.

Conditions

• Acute Myeloid Leukemia

Interventions

Type	Name	Description
DRUG	Interferon	Polyethylene glycol interferon alpha-2b injection 135 μg/week was subcutaneously given for 6 months.

Timeline

• Start date: 2023-01-01
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2025-01-31
• Last updated: 2025-01-31

Locations

1 site across 1 country: China